scholarly journals Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Kayoko Waki ◽  
Kouichiro Kawano ◽  
Naotake Tsuda ◽  
Kimio Ushijima ◽  
Kyogo Itoh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Plasma Levels ◽  
High Mobility ◽  
Suppressor Cell ◽  
Recurrent Ovarian Cancer ◽  
High Mobility Group ◽  
Peptide Vaccination ◽  
Clinical Trial Registry ◽  
Chi Square ◽  
Link Type

High-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into extracellular fluids from injured cells, activated macrophages, and tumor cells. The clinical correlation of circulating HMGB1 levels with various diseases including cancer has been reported. However, there is no information on HMGB1 levels in cancer patients treated with peptide vaccination. In the present study, we investigated the plasma levels of HMGB1 during personalized peptide vaccination in patients with recurrent ovarian cancer. Frozen plasma samples of 39 patients from previously conducted clinical trials were used in this study. HMGB1 levels were decreased after the 1st cycle of vaccination from their prevaccination levels. However, no correlation was observed between HMGB1 and overall survival (OS). The correlation between plasma HMGB1 levels and other biomarker levels was further analyzed by scatter plot, revealing that HMGB1 levels after the 1st cycle of vaccination were significantly correlated with myeloid-derived suppressor cell (MDSC) frequency after the 1st cycle of vaccination (r=0.357, p=0.032). Chi-square test showed that epitope spreading was significantly related with changes of HMGB1 (p=0.030). These results suggest that plasma HMGB1 is a possible biomarker for cancer vaccine therapy, although direct correlation with OS has not been obtained. This trial is registered with Clinical Trial Registry under trial numbers UMIN000003083 and UMIN000001482.

scholarly journals Association of plasma level of high-mobility group box-1 with necroptosis and sepsis outcomes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hongseok Yoo ◽  
Yunjoo Im ◽  
Ryoung-Eun Ko ◽  
Jin Young Lee ◽  
Junseon Park ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Validation Cohort ◽  
High Mobility ◽  
Kinase Domain ◽  
High Mobility Group ◽  
Rank Test ◽  
Enzyme Linked Immunosorbent Assay ◽  
Derivation Cohort ◽  
The Difference

AbstractThe role of high-mobility group box-1 (HMGB1) in outcome prediction in sepsis is controversial. Furthermore, its association with necroptosis, a programmed cell necrosis mechanism, is still unclear. The purpose of this study is to identify the association between the plasma levels of HMGB1 and the severity and clinical outcomes of sepsis, and to examine the correlation between HMGB1 and key executors of necroptosis including receptor-interacting kinase 3 (RIPK3) and mixed lineage kinase domain-like- (MLKL) proteins. Plasma HMGB1, RIPK3, and MLKL levels were measured with the enzyme-linked immunosorbent assay from the derivation cohort of 188 prospectively enrolled, critically-ill patients between April 2014 and December 2016, and from the validation cohort of 77 patients with sepsis between January 2017 and January 2019. In the derivation cohort, the plasma HMGB1 levels of the control (n = 46, 24.5%), sepsis (n = 58, 30.9%), and septic shock (n = 84, 44.7%) groups were significantly increased (P < 0.001). A difference in mortality between high (≥ 5.9 ng/mL) and low (< 5.9 ng/mL) HMGB1 levels was observed up to 90 days (Log-rank test, P = 0.009). There were positive linear correlations of plasma HMGB1 with RIPK3 (R2 = 0.61, P < 0.001) and MLKL (R2 = 0.7890, P < 0.001). The difference in mortality and correlation of HMGB1 levels with RIPK3 and MLKL were confirmed in the validation cohort. Plasma levels of HMGB1 were associated with the severity and mortality attributed to sepsis. They were correlated with RIPK3 and MLKL, thus suggesting an association of HMGB1 with necroptosis.

Increased Plasma Levels of High Mobility Group Box 1 in Patients with Acute Liver Failure

2012 ◽  
Vol 48 (3) ◽  
pp. 154-162 ◽  
Author(s):  
G. Oshima ◽  
M. Shinoda ◽  
M. Tanabe ◽  
H. Ebinuma ◽  
R. Nishiyama ◽  
...  
Keyword(s):  
Liver Failure ◽  
Acute Liver Failure ◽  
Plasma Levels ◽  
High Mobility ◽  
High Mobility Group

scholarly journals Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis

2015 ◽  
pp. 3523 ◽  
Author(s):  
Zengjun Li ◽  
Haipeng Wang ◽  
Yanlai Sun ◽  
Zhongfa Xu ◽  
Jianjun Han ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Meta Analysis ◽  
High Mobility ◽  
High Mobility Group ◽  
Cancer Tissue ◽  
Ovarian Cancer Tissue

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review

2020 ◽  
Vol 30 (5) ◽  
pp. 684-694
Author(s):  
Rebecca Arend ◽  
Shannon Neville Westin ◽  
Robert L Coleman
Keyword(s):  
Ovarian Cancer ◽  
Homologous Recombination ◽  
Maintenance Treatment ◽  
Recurrent Ovarian Cancer ◽  
Parp Inhibitors ◽  
Homologous Recombination Repair ◽  
Specific Patient ◽  
Link Type ◽  
Platinum Sensitive ◽  
Recombination Repair

Most women with ovarian cancer experience disease relapse, presenting numerous treatment challenges for clinicians. Maintenance therapy in the relapsed setting aims to extend the time taken for a cancer to progress, thus delaying the need for additional treatments. Four therapies are currently approved in the USA for secondline maintenance treatment of platinum sensitive, recurrent ovarian cancer: one antivascular endothelial growth factor agent (bevacizumab) and three poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (olaparib, niraparib, and rucaparib). In addition to efficacy, maintenance therapies must have a good tolerability profile and no significant detrimental impact on quality of life, as patients who receive maintenance are generally free from cancer related symptoms. Data from key bevacizumab trials (OCEANS, NCT00434642; GOG-0213, NCT00565851; MITO16B, NCT01802749) and PARP inhibitor trials (Study 19, NCT00753545; SOLO2, NCT01874353; NOVA, NCT01847274; ARIEL3, NCT01968213) indicate that bevacizumab and the PARP inhibitors are effective in patients with platinum sensitive, recurrent ovarian cancer but differ in their tolerability profiles. In addition, the efficacy of PARP inhibitors is dependent on the presence of homologous recombination repair deficiency, with patients with the deficiency experiencing greater responses from treatment compared with those who are homologous recombination repair proficient. Allowing for caveats of cross trial comparisons, we advise that clinicians account for the following points when choosing whether and when to administer a secondline maintenance treatment for a specific patient: presence of a homologous recombination repair deficient tumor; the patient’s baseline characteristics, such as platelet count and blood pressure; mode of administration of therapy; and consideration of future treatment options for thirdline and later therapy.

scholarly journals Serum high mobility group box protein 1 as a clinical marker for ovarian cancer

Neoplasma ◽  
2014 ◽  
Vol 62 (05) ◽  
pp. 579-584 ◽  
Author(s):  
Y. LI ◽  
J. TIAN ◽  
X. FU ◽  
Y. CHEN ◽  
W. ZHANG ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Mobility ◽  
High Mobility Group

scholarly journals Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study

2019 ◽  
Vol 334 ◽  
pp. 576993 ◽  
Author(s):  
Cynthia Marie-Claire ◽  
Cindie Courtin ◽  
Emmanuel Curis ◽  
Elodie Bouaziz-Amar ◽  
Jean-Louis Laplanche ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Pilot Study ◽  
Plasma Levels ◽  
High Mobility ◽  
High Mobility Group

scholarly journals Health impacts of a randomized biomass cookstove intervention in northern Ghana

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mona Abdo ◽  
Ernest Kanyomse ◽  
Rex Alirigia ◽  
Evan R. Coffey ◽  
Ricardo Piedrahita ◽  
...  
Keyword(s):  
Health Outcomes ◽  
Dried Blood Spots ◽  
Northern Ghana ◽  
Control Group ◽  
Clinical Trial Registry ◽  
Chi Square ◽  
Adverse Health Effects ◽  
Amyloid A ◽  
Link Type ◽  
Reported Health

Abstract Background Household air pollution (HAP) from cooking with solid fuels has adverse health effects. REACCTING (Research on Emissions, Air quality, Climate, and Cooking Technologies in Northern Ghana) was a randomized cookstove intervention study that aimed to determine the effects of two types of “improved” biomass cookstoves on health using self-reported health symptoms and biomarkers of systemic inflammation from dried blood spots for female adult cooks and children, and anthropometric growth measures for children only. Methods Two hundred rural households were randomized into four different cookstove groups. Surveys and health measurements were conducted at four time points over a two-year period. Chi-square tests were conducted to determine differences in self-reported health outcomes. Linear mixed models were used to assess the effect of the stoves on inflammation biomarkers in adults and children, and to assess the z-score deviance for the anthropometric data for children. Results We find some evidence that two biomarkers of oxidative stress and inflammation, serum amyloid A and C-reactive protein, decreased among adult primary cooks in the intervention groups relative to the control group. We do not find detectable impacts for any of the anthropometry variables or self-reported health. Conclusions Overall, we conclude that the REACCTING intervention did not substantially improve the health outcomes examined here, likely due to continued use of traditional stoves, lack of evidence of particulate matter emissions reductions from “improved” stoves, and mixed results for HAP exposure reductions. Clinical trial registry ClinicalTrials.gov (National Institutes of Health); Trial Registration Number: NCT04633135; Date of Registration: 11 November 2020 – Retrospectively registered. URL: https://clinicaltrials.gov/ct2/show/NCT04633135?term=NCT04633135&draw=2&rank=1

Sign in / Sign up

Export Citation Format

Share Document